title: ω-3 PUFAs and Resveratrol Differently Modulate Acute and Chronic Inflammatory Processes.
abstract: ω-3 PUFAs and polyphenols have multiple effects on inflammation in vivo and in vitro. The effects of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and resveratrol (RV) were investigated in LPS-stimulated peripheral blood leukocytes (PBLs) (i.e., acute inflammation) and IL-1β activated human chondrocytes (i.e., chronic inflammation). Inflammatory mediators including chemokines, cytokines, interleukins, and PGE2 were measured by multiplex analysis and gene expression was quantified by RT-PCR. In PBLs, RV decreased the secretion of PGE2, CCL5/RANTES, and CXCL8/IL-8 but increased IL-1β, IL-6, and IL-10. In contrast to RV, ω-3 PUFAs augmented the production of PGE2 and CXCL8/IL-8. EPA and DHA similarly affected the pattern of inflammatory mediators. Combination of RV and ω-3 PUFAs exerted synergistic effects on CCL5/RANTES and had additive effects on IL-6 or CXCL8/IL-8. Both ω-3 PUFAs and RV reduced catabolic gene expression (e.g., MMPs, ADAMTS-4, IL-1β, and IL-6) in activated chondrocytes. The data suggest that ω-3 PUFAs and RV differ in the regulation of acute inflammation of peripheral blood leukocytes but have common properties in modulating features related to chronic inflammation of chondrocytes.
authors: DSM Nutritional Products Ltd., Department of Human Nutrition & Health, P.O. Box 2676, 4002 Basel, Switzerland.
authors: Joseph
authors: J
authors: Schwager
authors: DSM Nutritional Products Ltd., Department of Human Nutrition & Health, P.O. Box 2676, 4002 Basel, Switzerland.
authors: Nathalie
authors: N
authors: Richard
authors: DSM Nutritional Products Ltd., Department of Human Nutrition & Health, P.O. Box 2676, 4002 Basel, Switzerland.
authors: Christoph
authors: C
authors: Riegger
authors: DSM Nutritional Products Ltd., 6480 Dobbin Road, Columbia, MD 21045, USA.
authors: Norman
authors: N
authors: Salem
mesh_terms: D000208:Acute Disease; D019902:Chondrocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002908:Chronic Disease; D004281:Docosahexaenoic Acids / Q000008:administration & dosage; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage* / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000139:chemically induced / Q000178:diet therapy* / Q000235:genetics / Q000473:pathology; D016753:Interleukin-10 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D016209:Interleukin-8 / Q000096:biosynthesis; D007962:Leukocytes / Q000187:drug effects*; D008070:Lipopolysaccharides / Q000633:toxicity; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: C508606:CXCL8 protein, human; D015525:Fatty Acids, Omega-3; C508609:IL10 protein, human; D015850:Interleukin-6; D016209:Interleukin-8; D008070:Lipopolysaccharides; D013267:Stilbenes; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid; D000077185:Resveratrol